Antibody-based therapy targeting tumor vascular endothelial cells suppresses solid tumor growth in rats.
We have developed a new approach to antibody-based therapy of solid tumors by targeting tumor vascular endothelial cells (EC) which are essential for the growth of solid tumors. We investigated the effect of an antibody against tumor-derived endothelial cells (TEC) on the growth of solid tumors in rats. Intravenous administration of TES-23, a monoclonal antibody generated by TEC isolated from rat KMT-17 solid tumors, at 1 mg/rat/day for 5 days resulted in significant suppression of KMT-17 tumor growth. Histopathological analysis of tumors administered with TES-23 showed that adhesion of lymphocytes to EC followed by denudation of EC in the viable tumor area. In contrast, little obvious toxicity was observed in most of the rat organs examined. These findings suggest that the concept of an antibody-based therapy with targeting tumor vascular EC would be promising in treatment of solid tumors.
Ohizumi
I
I
Department of Cancer Research, Chugai Pharmaceutical Co. Ltd., Shizuoka, Japan. ooizumiiwo@gt.chugai-pharm.co.jp
Tsunoda
S
S
Taniguchi
K
K
Saito
H
H
Esaki
K
K
Makimoto
H
H
Wakai
Y
Y
Tsutsumi
Y
Y
Nakagawa
S
S
Utoguchi
N
N
Kaiho
S
S
Ohsugi
Y
Y
Mayumi
T
T
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000920:Antibody-Dependent Cell Cytotoxicity; D004730:Endothelium, Vascular / Q000166:cytology / Q000276:immunology*; D005260:Female; D007167:Immunotherapy; D051381:Rats; D012513:Sarcoma, Experimental / Q000098:blood supply / Q000473:pathology / Q000628:therapy*
D000911:Antibodies, Monoclonal